Study Objectives: To determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana.

Study Design: Randomized clinical trial

Study Population: Pregnant women living with HIV and their infants

Study Duration: 24 months

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Study Findings

All regimens of HAART from pregnancy through 6 months post partum resulted in high rates of virologic suppression, with an overall rate of mother-to-child transmission of 1.1%.

Links to Study Publications and Reports
Antiretroviral regimens in pregnancy and breast-feeding in Botswana
HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana
In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana
Vitamin D insufficiency in HIV-infected pregnant women receiving antiretroviral therapy is not associated with morbidity, mortality or growth impairment in their uninfected infants in Botswana
Cotrimoxazole prophylaxis and risk of severe anemia or severe neutropenia in HAART-exposed, HIV-uninfected infants
Increased risk of severe infant anemia after exposure to maternal HAART, Botswana
Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in Botswana